Margaret Liu

The Ohio State University

H指数:30

被引数:3,219

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment

将抗体药物偶联物与cmLumiOpto结合用于三阴性乳腺癌治疗

Cell Reports Medicine

IF10.6

2026-07-240

OAAI

Correction: Si et al. Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment. Pharmaceutics 2020, 12, 1079

更正：Si等人. 双靶向外泌体以促进神经内分泌癌症治疗中的联合疗法。Pharmaceutics 2020, 12, 1079

Pharmaceutics 2025, Vol. 17, Page 1317

IF0

2025-10-110

OAAI

Real-World Effectiveness of the MiniMed™ 780G Advanced Hybrid Closed-Loop System for People ≥65 Years with Type 1 or Type 2 Diabetes in the United States

美国≥65岁1型或2型糖尿病患者使用MiniMed™ 780G先进混合闭环系统的真实世界有效性

Diabetes Technology & Therapeutics

IF6.3

2025-09-160

PRE

Optogenetic mitochondrial preconditioning enhances cardiomyocyte survival under stress

光遗传线粒体预适应增强心肌细胞在应激下的存活率

Journal of Molecular and Cellular Cardiology

IF4.7

2025-06-080

The impact of international sanctions on food security and Sustainable Development Goal 2 (SDG-2)

PUBLIC HEALTH

IF3.2

2024-10-011

PRE

CARDIAC TAMPONADE MASQUERADING AS ST ELEVATION MYOCARDIAL INFARCTION: A CASE REPORT

CHEST

IF8.6

2024-10-010

PRE

mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer

CANCER RESEARCH

IF16.6

2024-09-170

OAAI

Generating real-world evidence on diabetes technology using the CareLink Personal data management system

DIABETES OBESITY & METABOLISM

IF5.7

2024-09-041

A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer

CANCER RESEARCH

IF16.6

2024-08-261

OAAI

Dual payload immunochemotherapy to treat CD276 positive cancers

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Advanced biomanufacturing and evaluation of adeno-associated virus

腺相关病毒的先进生物制造和评估

JOURNAL OF BIOLOGICAL ENGINEERING

IF6.5

2024-02-152

OAAI

Characterization of the far-red fluorescent probe MitoView 633 for dynamic mitochondrial membrane potential measurement

FRONTIERS IN PHYSIOLOGY

IF3.4

2023-10-234

OAAI

A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC)

一种治疗非小细胞肺癌 (NSCLC) 的CD276-Targeted抗体-药物偶联物

CELLS

IF5.2

2023-09-301

OAAI

Starch and sugars as determinants of postharvest shelf life and quality: some new and surprising roles

CURRENT OPINION IN BIOTECHNOLOGY

IF7

2022-12-0127

OAAI

An enhancer variant associated with breast cancer susceptibility in Black women regulates TNFSF10 expression and antitumor immunity in triple-negative breast cancer

HUMAN MOLECULAR GENETICS

IF3.2

2022-08-057

OAAI

Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers

Anti-CD47单克隆抗体-药物偶联物: 治疗三阴性乳腺癌的靶向治疗

VACCINES

IF3.4

2021-08-1022

OAAI

Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment (vol 167, pg 189, 2020)

SURGERY

IF2.7

2021-07-010

OAAI

Robust Glycemic Outcomes after MiniMed Advanced Hybrid Closed-Loop (AHCL) System Use in the Pivotal Trial Regardless of Previous Therapy

DIABETES

IF7.5

2021-06-011

PRE

Antibody-Drug Conjugate to Treat Meningiomas

PHARMACEUTICALS

IF4.8

2021-05-026

OAAI

Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment

PHARMACEUTICS

IF5.5

2020-11-1116

OAAI

Margaret Liu

个人简介

教育背景

工作经历

荣誉奖项

研究方向